Breaking News

Andromeda Acquires Teva’s DiaPep277 Rights

By Kristin Brooks | February 24, 2014

Will pursue current Phase III development program in type 1 diabetes

Andromeda Biotech Ltd. has entered an agreement with Teva Pharmaceutical Industries Ltd. to acquire Teva's rights for Andromeda's drug DiaPep277 for the treatment of type 1 diabetes. Teva will transfer its DiaPep277 rights and all of its shares in Andromeda, for total of approximately $72 million, payable in installments through future payments based on Andromeda's revenues or on proceeds payable to its shareholders.
 
Andromeda will work to ensure that the current Phase III development program of DiaPep277 will continue according to plan, without delays in an effort to gain regulatory approval.
 
 
 

Related Contract Manufacturing:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers